Last C$0.57 CAD
Change Today -0.04 / -6.56%
Volume 378.5K
LPS On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 3:25 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
McClatchy-Tribune  07/17/2014 3:39 PM ET
Mori Arkin in talks to acquire Sol-Gel [Globes, Tel Aviv, Israel :: ]

July 17--Businessman Mori Arkin is in advanced talks to buy Sol-Gel, which is developing skincare products using nanotechnology, sources inform "Globes." If the deal goes through, Arkin will pay $10 million, or more, if milestones are met. The company has confirmed the report.

Sol-Gel, managed by Dr. Alon Seri-Levy, has developed a method of wrapping molecules with nanoscale particles in order to help the materials inside penetrate the skin. While the active ingredients in Sol-Gel are mostly generic, the wrapping is unique technology, which is meant to improve the performance of the drug.

The company's lead products are a treatment of the skin condition rosacea, which has completed Phase II clinical trials, and an acne treatment, which is about to begin Phase II trials.

Sol-Gel is a veteran company, which was established in 1997. Since its founding, $26 million has been invested by leading Israeli and foreign venture capital firms, including Argonaut, Challenge Fund -- Etgar, and Jerusalem Venture Partners (JVP). In 2008, the company had a "mini-exit," when it sold some of its sun-protection technology to Merck & Co. for $10 million.

The investors did not cash out of the company, but instead invested in the product portfolio, in an attempt to reach a larger exit. However, the funds that invested in Sol-Gel have reached the end of their investment period, and are currently considering accepting Arkin's offer.

The rosacea product completed Phase II clinical trials in 2012, but the company did not find a suitable partner with whom to proceed to Phase III, or the funding to enable it to lead the process along. The product is a substance called benzoyl peroxide, which is currently used to treat acne, not rosacea, because the medicine itself causes skin irritation in rosacea sufferers. The version with Sol-Gel's wrapper, which enables extended release of the drug, is meant to make it suitable for these patients as well.

Similar developments

Sol-Gel conducted negotiations to register its product with a few leading companies in recent years, including a deal that was meant to yield $150 million for the company if the product succeeded. However, the corporation with which the company negotiated decided that the product was still in too early a stage of development. If the product develops and the deal with the corporation is signed, Sol-Gel will receive an additional $7 million from Arkin.

Mori Arkin is a member of the family that founded Agis, which was also active in the field of dermatology. Arkin led the company to its sale to Perrigo Company (NYSE:PRGO; TASE:PRGO) for $900 million in cash and shares, and has been investing in biomed and other fields since that time (including an investment in Bezeq Israeli Telecommunication Co. Ltd. (TASE: BEZQ)).

Arkin Holdings is currently amassing various technologies in the field of dermatological R&D, and has invested in Foamix, which is also developing treatments for rosacea and acne, but with a different, foam-based delivery method. In response to the question of why he chose to invest in two companies with similar developments, Arkin said, "There are enough zits for everyone."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPS:CN C$0.57 CAD -0.04

Industry News

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEGEND POWER SYSTEMS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.